Stay updated on Nivolumab vs Docetaxel in NSCLC: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.

Latest updates to the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page; this is a minor metadata update with no changes to study content, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe study location sections were consolidated under a single 'Locations' heading and list the regions (Beijing Municipality, Chongqing Municipality, Fujian, Guangdong, Henan, Hunan, Jiangsu, Jilin, Shanghai Municipality, Sichuan, Zhejiang). The previous per-location 'X Locations' subsections were removed and a revision note (Revision: v3.3.3) was added.SummaryDifference1%

- Check52 days agoChange DetectedAdded a PubMed auto-fill note clarifying that publications may not all relate to the study. Updated the revision label to v3.3.2 (replacing the prior v3.2.0 wording).SummaryDifference0.1%

- Check59 days agoChange DetectedRemoval of the site-wide government funding notice. This administrative change does not affect the trial details presented on the page.SummaryDifference0.3%

- Check73 days agoChange DetectedNo significant differences observed between the two screenshots; the page content and structure appear unchanged.SummaryDifference0.3%

- Check102 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference3%

Stay in the know with updates to Nivolumab vs Docetaxel in NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.